UROKINASE--EFFECT ON SURGERY PLUS BCG FOR BLADDER CANCER

尿激酶——联合卡介苗治疗膀胱癌的手术效果

• 批准号: 2095789
• 负责人: M'LISS ANN HUDSON
• 金额: $ 11万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-04-01 至 1996-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2095789
• 关键词: Mycobacterium bovis; binding proteins; bladder neoplasm; chemical carcinogen; disease /disorder model; enzyme inhibitors; enzyme mechanism; fibronectins; laboratory mouse; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; urokinase

DESCRIPTION: (Adapted from applicant's abstract) The purpose of these studies is to investigate the effect of u-PA on the antitumor efficacy of BCG therapy for superficial bladder cancer, to investigate the potential role of monitoring u-PA levels as a predictor of response to BCG therapy, and to investigate methods of enhancing BCG therapy through modulation of u-PA activity. Initial studies will assess the effect of a standard preparation of u-PA on the BCG-FN interaction and antitumor efficacy in vitro and in a murine bladder tumor model. Further studies will correlate naturally occurring u-PA activity, receptor levels and secretion in normal and malignant urothelium with BCG-FN attachment and antitumor efficacy in tissue culture and a murine bladder tumor model. Finally, an enhanced antitumor effect will be sought with the use of u-PA inhibitors in conjunction with intravesical BCG therapy.

描述：（改编自申请人的摘要）这些的目的 研究目的是探讨u-PA对抗肿瘤功效的影响 卡介苗治疗浅表性膀胱癌的潜力 监测 u-PA 水平作为 BCG 治疗反应预测因子的作用， 并研究通过调节增强 BCG 治疗的方法 u-PA 活性。 初步研究将评估标准的效果 u-PA制备对BCG-FN相互作用及抗肿瘤功效的影响 体外和小鼠膀胱肿瘤模型中。 进一步的研究将关联 正常情况下天然存在的 u-PA 活性、受体水平和分泌 和具有 BCG-FN 附着的恶性尿路上皮及其抗肿瘤功效 组织培养和小鼠膀胱肿瘤模型。 最后，一个增强的 u-PA抑制剂的使用将寻求抗肿瘤作用 与膀胱内 BCG 治疗相结合。